Skip to main content

Table 1 Laboratory parameters of participants with EOTs

From: Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors

Variable

Malignant

Borderline

Benign

Reference level

P-value

Number

64

64

156

  

W (109/L)

6.55 ± 3.26

5.91 ± 1.31

5.79 ± 1.91

3.5–9.5

0.0549

N (109/L)

4.58 ± 3.20

3.54 ± 1.21

2.82 ± 1.42

1.8–6.3

< 0.001abc

L (109/L)

1.51 ± 0.54

1.86 ± 0.55

2.10 ± 0.62

1.1–3.2

< 0.001abc

Mo (109/L)

0.35 ± 0.15

0.36 ± 0.10

0.36 ± 0.13

0.1–0.6

0.868

PLT (109/L)

253.8 ± 83.24

242.9 ± 59.16

189.8 ± 56.40

125–350

< 0.001bc

PDW (fL)

13.33 ± 2.61

13.56 ± 2.10

13.86 ± 2.95

9.6–15.2

0.5594

RDW (%)

42.63 ± 5.33

41.48 ± 2.36

42.10 ± 2.98

41.2–53.6

0.3279

PLR

193.3 ± 103.35

140.2 ± 49.61

80.61 ± 25.85

/

< 0.001abc

NLR

3.87 ± 6.02

2.15 ± 1.39

1.19 ± 0.47

/

< 0.001abc

MLR

0.27 ± 0.20

0.21 ± 0.07

0.15 ± 0.05

/

< 0.001abc

CA125 (U/ml)

90.57 ± 75.22

39.48 ± 47.37

12.41 ± 3.37

0–35

< 0.001abc

HE4 (pmol/L)

128.00 ± 186.14

58.64 ± 30.44

52.56 ± 11.01

premenopause < 70

postmenopause< 140

< 0.001ac

  1. W white blood cell count, N absolute neutrophil count, L absolute lymphocyte count, Mo absolute monocyte count, PLT blood platelet count, PDW platelet distribution width, RDW red cell distribution width, PLR platelet/lymphocyte ratio, NLR neutrophil/lymphocyte ratio, MLR monocyte/lymphocyte ratio, CA125 cancer antigen 125, HE4 human epididymis protein 4
  2. a the difference between malignant and borderline EOTs was statistically significant
  3. b the difference between borderline and benign EOTs was statistically significant
  4. c the difference between malignant and benign EOTs was statistically significant